Christopher Haqq - Executive Vice President, Head of R&D and Chief Medical Officer at Elicio Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Executive Vice President, Head of R&D and Chief Medical Officer
Issuer Symbol
ELTX on Nasdaq
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Christopher Haqq since 11 Feb 2025

Holdings reported by Christopher Haqq for Elicio Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 57,381 $456,752 $7.96 02 Feb 2026 Direct
Stock Option (Right to Buy) 50,900 02 Feb 2026 Direct Common Stock

Transactions reported by Christopher Haqq for Elicio Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.